KURA Kura Oncology Inc
Price (delayed)
$6.18
Market cap
$499.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$291.2M
Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable
Highlights
The company's EPS rose by 14% QoQ and by 2.9% YoY
The debt has declined by 3.5% year-on-year
Kura Oncology's net income has decreased by 14% YoY but it has increased by 12% from the previous quarter
The equity has grown by 4.1% YoY but it has contracted by 2.4% from the previous quarter
The quick ratio has contracted by 23% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of KURA
Market
Valuations
Earnings
Shares outstanding
80.75M
Market cap
$499.07M
Enterprise value
$291.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
9.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.4
Revenue
$53.88M
Gross profit
$53.88M
Operating income
-$193.2M
Net income
-$173.98M
EBIT
-$170.35M
EBITDA
-$169.5M
Free cash flow
$133.85M
Per share
Balance sheet
Liquidity
EPS
-$2.02
EPS diluted
-$2.02
Free cash flow per share
$1.55
Book value per share
$5.32
Revenue per share
$0.63
TBVPS
$8.82
Total assets
$760.16M
Total liabilities
$346.52M
Debt
$16.59M
Equity
$413.64M
Working capital
$666.12M
Debt to equity
0.04
Current ratio
9.46
Quick ratio
9.24
Net debt/EBITDA
1.23
Margins
Efficiency
Dividend
EBITDA margin
-314.6%
Gross margin
100%
Net margin
-322.9%
Operating margin
-358.5%
Return on assets
-30.2%
Return on equity
-38.5%
Return on invested capital
-37.2%
Return on capital employed
-25%
Return on sales
-316.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KURA stock price
How has the Kura Oncology stock price performed over time
Intraday
4.75%
1 week
5.64%
1 month
-21.17%
1 year
-64.75%
YTD
-29.05%
QTD
-6.36%
Financial performance
How have Kura Oncology's revenue and profit performed over time
Revenue
$53.88M
Gross profit
$53.88M
Operating income
-$193.2M
Net income
-$173.98M
Gross margin
100%
Net margin
-322.9%
The company's operating income fell by 17% YoY but it rose by 11% QoQ
Kura Oncology's net income has decreased by 14% YoY but it has increased by 12% from the previous quarter
Growth
What is Kura Oncology's growth rate over time
Valuation
What is Kura Oncology stock price valuation
P/E
N/A
P/B
1.16
P/S
9.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.4
The company's EPS rose by 14% QoQ and by 2.9% YoY
The stock's P/B is 62% below its last 4 quarters average of 2.9 and 57% below its 5-year quarterly average of 2.6
The equity has grown by 4.1% YoY but it has contracted by 2.4% from the previous quarter
Efficiency
How efficient is Kura Oncology business performance
The ROA has grown by 24% from the previous quarter and by 9% YoY
The return on invested capital has increased by 17% since the previous quarter
The return on equity has grown by 13% since the previous quarter but it has declined by 6% year-on-year
Dividends
What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KURA.
Financial health
How did Kura Oncology financials performed over time
KURA's total assets is 119% greater than its total liabilities
KURA's total assets has surged by 69% year-on-year and by 59% since the previous quarter
The current ratio fell by 23% YoY and by 18% QoQ
The debt is 96% smaller than the equity
The equity has grown by 4.1% YoY but it has contracted by 2.4% from the previous quarter
The debt has declined by 3.5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.